Table 2. Open in new tab Arboviral...

DENV Immune Status^a		ZIKV Immune Status^b		CHIKV Immune Status^c
Naive	57	52	5	53	4
DENV1	9	8	1	9	0
DENV2	11	10	1	11	0
DENV3	7	6	1	6	1
DENV4	2	2	0	2	0
Secondary	6	6	0	6	0
Total	92	84	8	87	5

DENV Immune Status^a		ZIKV Immune Status^b		CHIKV Immune Status^c
Naive	57	52	5	53	4
DENV1	9	8	1	9	0
DENV2	11	10	1	11	0
DENV3	7	6	1	6	1
DENV4	2	2	0	2	0
Secondary	6	6	0	6	0
Total	92	84	8	87	5

Table 2.

Arboviral Serostatus of 17D Vaccinees

DENV Immune Status^a		ZIKV Immune Status^b		CHIKV Immune Status^c
		Naive	Positive	Naive	Positive
Naive	57	52	5	53	4
DENV1	9	8	1	9	0
DENV2	11	10	1	11	0
DENV3	7	6	1	6	1
DENV4	2	2	0	2	0
Secondary	6	6	0	6	0
Total	92	84	8	87	5

DENV Immune Status^a		ZIKV Immune Status^b		CHIKV Immune Status^c
		Naive	Positive	Naive	Positive
Naive	57	52	5	53	4
DENV1	9	8	1	9	0
DENV2	11	10	1	11	0
DENV3	7	6	1	6	1
DENV4	2	2	0	2	0
Secondary	6	6	0	6	0
Total	92	84	8	87	5

Abbreviations: CHIKV, chikungunya virus; DENV, dengue virus; PRNT₅₀, 50 percent plaque reduction neutralization test; ZIKV, Zika virus.

^aSubjects with PRNT₅₀ ≥1:20 against only 1 serotype or with a PRNT₅₀ against 1 serotype that was 4-fold higher than the other serotype were classified as primary for the highest titer serotype. All other DENV seropositive subjects were classified as secondary.

^bSubjects with PRNT₅₀ ≥1:20 against ZIKV were classified as ZIKV positive.

^cSubjects with PRNT₉₀ ≥1:20 against CHIKV were classified as CHIKV positive.

This Feature Is Available To Subscribers Only